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ABSTRACT
The availability of tyrosine kinase inhibitors (TKI) during the past ten years has 
led to improved response and overall survival of patients suffering from metastatic 
clear cell renal cell carcinoma (ccRCC). However, most of these tumors will eventually 
progress due to resistance evolving under therapy. The objective of this pilot study 
was to determine whether molecular alterations in ccRCC tissues sampled over the 
course of the disease might be suggestive of potential therapies. We performed whole 
exome sequencing of nine samples from four patients in the MORE (Molecular Renal 
Cancer Evolution) trial. We analyzed the mutational patterns in the tissues at baseline 
and compared them to those detectable in biopsy samples after progression under TKI 
therapy. We found limited genetic concordance between primary and secondary tumor 
sites with private mutations in FLT4, MTOR, ITGA5, SETD2, PBRM1, and BRCA1 on 
progression. One patient who showed an increased mutational load in the metastasis 
responded to nivolumab treatment. Our data provide evidence for clonal evolution and 
diverse pathways leading to acquired TKI resistance of ccRCC. Acquired resistance 
to TKI in metastatic ccRCC is due to intra-tumor heterogeneity and clonal evolution 
of resistant subclones. Mutations occurring under progression might be informative 
for alternative targeted therapies.
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INTRODUCTION
Kidney cancer represents one of the most frequent 
malignant neoplasms in the United States [1]. About 
80% of kidney tumors belong to the clear cell renal cell 
carcinoma (ccRCC) histology. Thirty percent of ccRCC 
patients develop metastatic disease (mRCC), which is 
associated with poor prognosis and short overall survival 
(OS) [2]. However, since the approval of the first targeted 
drug (sorafenib) in 2005, the therapeutic landscape has 
changed considerably, and OS of mRCC increased from 
nine months in 2005 to 30 months in 2011 [3]. Today, 
approved targeted drugs for ccRCC include tyrosine-
kinase inhibitors (TKI), mTOR pathway inhibitors and 
antibodies against the vascular endothelial growth factor 
(VEGF). In particular, TKIs such as sunitinib, which 
target multiple receptors at the same time, have been 
highly successful in the treatment of mRCC patients [4]. 
Currently, ten different drugs are approved for first- 
and second-line therapy [5–10]. The efficacy of these 
agents is highest in the first-line setting with the choice 
of agent class being important for OS [11]. However, 
the optimal sequence of targeted drugs is unknown due 
to a lack of biomarkers for patient stratification [12, 13]. 
On the molecular level, ccRCC is a heterogeneous 
tumor displaying a broad spectrum of genetic alterations 
[14, 15]. Multiregion sequencing revealed intra-tumor 
heterogeneity of mRCC with wide subclonal diversity 
[16–18]. Here, we report the results of a pilot study 
(MORE, Molecular Renal Cancer Evolution) using whole-
exome sequencing (WES) of primary and biopsy tissue 
samples from treatment-naïve patients at baseline and after 
TKI treatment respectively. Our aim was to assess whether 
genetic alterations that can be exploited therapeutically 




Four of the 17 patients enrolled in the MORE study 
(Table 1) showed progression under TKI treatment. At 
these time points, metastasis biopsies were collected, 
and DNA from tumor tissues at baseline and progression 
was subjected to WES. Patient 1 (female, 81.3 years) 
progressed under sunitinib therapy after 5.4 months, and 
a biopsy (vaginal wall metastasis) was taken (Figure 1). 
Patient 2 (female, 70.5 years) progressed after 6.2 months 
under sunitinib therapy. After needle biopsy from the 
right chest wall, the therapy was continued with axitinib 
until she suffered a second progression after 11.8 months 
(Figure 1). Patient 3 (male, 46.3 years) showed no residual 
malignant disease after cytoreductive nephrectomy and 
adjuvant sunitinib treatment. At relapse after 6.1 years 
(73 months), a baseline biopsy of the left chest wall 
metastasis was taken, and treatment was continued with 
pazopanib. He progressed at 3.9 months and the therapy 
was switched to everolimus, which was discontinued 
after 1.8 months due to clinical progression (soft tissue 
metastasis). After re-biopsy of the chest wall metastasis, 
nivolumab treatment was initiated (Figure 1). Patient 4 
(male, 58.9 years), progressed after 5.3 months sunitinib 
treatment, and a biopsy was collected from the os ilium. 
In addition, a cutaneous nodule in the left chest wall could 
be resected when he progressed after 6 months on axitinib 
(Figure 1). The therapy was continued with everolimus 
for 1.5 months, followed by pazopanib for 2 months. The 
patient died of the disease soon thereafter.
Molecular analysis at baseline and tumor 
progression
To evaluate clonal diversity and molecular 
alterations upon progression on TKI treatment of the four 
patients (Nr. 1-4), we performed WES of the primary 
tumor and biopsy samples from metastatic sites upon 
disease progression (Figure 1). Matched buffy coat 
samples were sequenced to exclude germline alterations 
from sequencing data. Sequencing of tumor and and 
matched buffy coat resulted in a mean target coverage of 
124× and revealed an average of 486 non synonymous 
somatic mutations (Table 2, Supplementary Table 1) with 
a mean coverage of 104× at mutation sites. Mutations in 
RCC-associated genes, including VHL, BAP1, PBRM1, 
LRP1B, and KMT2C were further validated by Sanger 
sequencing. Consistent with previous reports [16, 17], 
the genetic compositions among the four patients were 
diverse (Figure 2), with alterations in genes known to be 
recurrently mutated in ccRCC, i.e. VHL, SETD2, PBRM1, 
and BAP1 [14, 15] and others which are known oncogenes 
or might be potential therapy targets. These selected 
genes are shown in Figure 3. All somatic nonsynonymous 
mutations and their resulting effect on transcripts and 
proteins are given in Supplementary Table 1. 
We found remarkable heterogeneity between 
primary and metastatic lesions with only a small subset 
of alterations present in both sites (Figure 2): WES 
of the primary tumor from patient 1 identified private 
mutations in the tumor suppressor genes PTEN and 
APC as well as in HRAS, BCAR1 (COSM1479104), and 
SETD1A (COSM126103). Forty mutations, including 
in VHL (COSM14311), BAP1, and STK25 were shared 
between primary and metastatic site (Figure 3, Patient 1). 
The metastasis upon progression under sunitinib carried 
mutations in FLT4, KMT2D, and BMP5, which were not 
detected in the primary tumor. We identified 55 mutations 
shared between primary tumor and metastasis of patient 2 
(Figure 2A), including BAP1, LRP1B, and BCAR1. She 
had a private mutation in PIK3CA (COSM1041490) 
in the primary tumor. In line with previous findings 
suggesting that mTOR mutations occur predominantly 
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at advanced stages of tumor evolution in subclonal 
metastatic populations [16, 17], the metastasis revealed a 
private mTOR mutation. Additional mutations were found 
in FGFR1 and ERBB2 (Figure 2). After cytoreductive 
nephrectomy and adrenalectomy of the left kidney, patient 
3 was treated with sunitib and showed no evidence of 
residual disease or indications of progression during 
follow-up. When the tumor relapsed after more than 
six years with synchronous bone, pleural and chest wall 
metastases, a biopsy from the left chest wall metastasis was 
used as a baseline sample. After progression on pazopanib 
and everolimus, this metastasis was re-biopsied, and the 
therapy was continued with nivolumab. WES analysis 
showed an increase of mutational load between baseline 
(81 mutations) and progression (251 mutations), and 32 
(39.5%) of the 81 baseline mutations were also found in 
the re-biopsy (Figure 3), including changes in VHL, BAP1, 
KMT2C, CSMD3, and FAT3. The re-biopsy revealed 
additional private mutations in the epigenetic regulators 
KMT2D (COSM1299437) and KMT2E (COSM1083684) 
as well as in PBRM1, one of the most frequently mutated 
genes in ccRCC, which codes for a subunit of the BAF 
chromatin remodeling complex. Furthermore, we detected 
a mutation in BRCA1, which was not been present at 
baseline. In patient 4, WES of the primary tumor and two 
different locations of metastases was performed (Figure 
2A, 2B). Only three (RYR3, ABI3BP, and TMEM255A) 
of the 1445 identified nonsynonymous somatic mutations 
were found to be present at every site. Notably, the 
mutational spectrum of the primary tumor revealed a 
larger overlap with the chest wall metastasis than with 
the initial pelvic bone metastasis (30 vs. 5 mutations, 
respectively), including changes in VHL and PBRM1, 
possibly indicating an early separation of the cells giving 
rise to the latter metastasis. The analysis of the chest wall 
metastasis identified further mutations in cancer-associated 
genes, including SETD2 and ERBB2. In addition, with 
700 somatic variants, the mutational load of the chest wall 
metastasis was considerably higher than in the primary 
tumor and the metastasis located in the os ilium (371 
and 342 mutations, respectively). This suggests an early 
separation of cells giving rise to the chest wall lesion.
DISCUSSION
The current pharmacological treatment strategies in 
ccRCC are based on targeted drugs and, more recently, 
immune checkpoint inhibitors. Although numerous 
TKIs are available, tumor heterogeneity and secondary 
resistance are major challenges for cancer therapy. 
Especially a heterogeneous phenotypic response to TKI 
therapy and progression has recently been found [19]. 
Hence, a deeper understanding of the complexity of 
molecular and mutational signatures of ccRCC is 
needed. This can be achieved with the ultra-high DNA 
sequencing. However, apart from large catalogues of 
somatic mutations in cancer including ccRCC [14, 15] 
provided by international sequencing projects like TCGA 
and ICGC, multiregional sequencing also revealed 
remarkable intra-tumor heterogeneity [16–18, 20] Here, 
we provide evidence for considerable temporal molecular 
heterogeneity between therapy-naïve primary tumors and 
metastases developing under TKI. The mutational profiles 
provide insights into clonal evolution occuring during 
tumor progression under therapy: Molecular profiling 
revealed recurrent genomic alterations in genes frequently 
altered in ccRCC [14], including VHL, SETD2, and 
BAP1. Deletions of the VHL tumor suppressor gene are 
occuring early during tumorigenesis of ccRCC [16]. We 
detected additional VHL mutations in baseline samples 
and metastatic sites in three out of four patients. Well-
known alterations were found to be common to primary 
and metastatic sites. These included mutations in the 
ccRCC tumor-driving gene BAP1 in patients 1, 2, and 3. 
The clonality of the BAP1 mutation, which has been 
associated with poor prognosis and a high metastasizing 
Figure 1: Swimmer plot with therapy sequences and durations of different treatment lines for each patient. The different 
therapies are indicated by colors and include nephrectomy, radiation therapy, and biopsies from progressive sites.
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potential [21] supports BAP1 as a molecular marker for 
ccRCC sub-classification [21]. 
In agreement with previous reports [16, 17], our WES 
results revealed that mTOR mutations occur predominately 
in subclonal branches in advanced disease stages (patient 2). 
We also identified two different ITGA5 mutations in 
independent metastases, but not in the primary tumor, of 
patient 4, suggesting parallel evolution of the two metastatic 
clones. In contrast to patients 1–3, most of the mutations 
in patient 4 were found to be private for each sample. This 
might be due to several reasons: Either the initial molecular 
features present in the primary tumor were lost in the 
metastases, or multiple novel mutations accumulated in 
the metastases, or the sequenced tissue region in primary 
tumor did not contain the clones that gave rise to the 
metastases. Although we cannot distinguish between these 
possibilities, all of them are consistent with a high molecular 
heterogeneity present early during tumor development, 
followed by clonal selection and/or independent evolution 
after dissemination of tumor cells. Supported by previous 
findings in breast cancer [22], the larger overlap of the 
primary tumor with the chest wall metastasis than with the 
initial pelvic bone metastasis possibly indicates an early 
separation of the cells giving rise to the latter metastasis.
The identification of clinically relevant mutations 
upon tumor progression under TKI treatment suggests that 
it might be possible to derive alternative targeted therapies 
based on molecular changes in the metastases. The 
analysis of the molecular patterns upon TKI progression 
revealed different potentially targetable mutations in all 
cases tested. While we detected subclonal mutations in 
FLT4, ITGA5, SETD2, and BRCA1 in the metastases, 
one patient developed mutations in mTOR and several 
receptor tyrosine kinase genes, including ERBB2, ERBB4, 
and FGFR1. Moreover, the chest wall re-biopsy of patient 
3 exhibited mutations in PBRM1 and BAP1, which are 
mostly mutually exclusive. Their co-occurrence has been 
associated with aggressive tumors and poor prognosis 
[23, 24]. The acquired BRCA1 mutation, which was not 
detected in the baseline of patient 3, represents another 
Figure 2: Clonal mutations in primary and metastatic sites. Numbers of exclusive and shared mutations identified in primary 
tumor tissue and metastasis biopsies (A). Coding mutations in the primary tumor and metastasis biopsies from patient 4 (B).
Table 1: Clinical characteristics of the four patients who experienced tumor progression
Patient 1 Patient 2 Patient 3 Patient 4
Age (y) 81.3 70.5 46.3 46.3
Gender F F M M
TNM T4N2M1 T1aN0M1 T3bN2M1 T3aN2M1
Fuhrman Grade G3 G2 G2 G3
Site of metastasis paraaortal lymph node, lung, bilataral adrenal, cava thrombus lung, bone, liver
retroperineal lymph node, 
bone, chest wall, pleura lung, bone, adrenal
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Figure 3: Coding somatic mutations identified in primary tumors and metastatic sites at baseline and upon progression. 
The upper histogram shows the number of nonsynonymous mutations per sample. The heatmap indicates the presence (blue) and absence 
(grey) of mutations in selected cancer-associated genes in primary and progressive samples of the four patients. The lower histogram shows 
the proportions of base substitutions for each sample.
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impairment of DNA repair, which might indicate that 
PARP inhibitors could be beneficial in this case. Activity 
of PARP in BRCA-mutated ovarian and prostate cancer 
is well established and olaparib is clinically approved 
[25, 26]. Activity of PARP inhibitors in BRCA-mutated 
ccRCC has not yet been reported. However, the molecular 
principle remains similar through different entities, and 
an individual treatment approach after failure of approved 
substances may be warranted. Alternatively, BRCA1 
mutations giving rise to impaired DNA repair may result in 
increased expression of neoantigens, a potential marker of 
sensitivity to immune checkpoint inhibitors. Furthermore, 
VEGFR3/FLT4 inhibitors that are currently in early 
clinical development may be active in patients carrying 
VEGFR3/FLT4 mutations, respectively [27]. Mutations in 
mTOR may be particularly sensitive to mTOR inhibitory 
drugs. Finally, several drugs targeting the FGFR are 
currently under clinical development. 
To the best of our knowledge, this study is the first 
to examine molecular alterations associated with ccRCC 
therapy resistance in tissue DNA in a longitudinal fashion. 
The molecular data provide evidence for various routes 
leading to drug resistance of ccRCC subclones with 
acquired mutations in known therapy target genes on 
metastatic progression. 
The major limitation of our study is its small sample 
size due to the low progression rate to date, and our 
findings have to be corroborated in larger studies. To this 
end, MORE is open and actively recruiting, and we will 
provide an extension of the current data set in due time. 
However, our results agree with comparable precision 
medicine approaches in other tumor entities in that the 
progression of patients under therapy is very specific and 
restricted to the individual case. In other words, highly 
recurrent targetable mutations cannot be expected from 
the analysis of many more cases. In contrast, the serial 
molecular analysis of tumors from individual ccRCC 
patients progressing under therapy might indicate 




The MORE (Molecular Renal Cancer Evolution) 
study is a prospective clinical study designed to investigate 
molecular alterations in metastatic ccRCC progressing 
under first-line TKI. The primary objective of MORE is 
to characterize molecular alterations in metastatic lesions 
compared to baseline tissue in order to understand the 
individual factors leading to therapy resistance and tumor 
progression. Secondly, we hope to identify potential 
molecular targets for personalized therapies for the 
progressive patients in order to improve individual patient 
care. The study was approved by the ethics committee at 
the Heidelberg University Medical Faculty (S-539/2013) 
and listed on clinicaltrials.gov (NCT02208128) and the 
national study register (DRKS0006193). Patients with 
metastatic disease and no prior systemic therapy were 
eligible for the study. At baseline, tissue samples from 
debulking primary tumor surgery or biopsy samples were 
taken. After standard of care first and second line therapies, 
biopsies of progressing metastases were sampled. 
Patients and samples
Seventeen patients were classified as low risk 
according to the MSKCC [8] prognostic score and had 
pure clear cell histology at baseline and progression. These 
Table 2: Sample characteristics and quality metrics of the sequencing data








Tumor Baseline right kidney 106.03 86.11 166 720
Metastasis 1. Progress left vaginal wall 121.8 85.63 169 760
Buffy Coat Baseline blood 109.93 88.83 171 -
Patient 2
Tumor Baseline left kidney 111.81 85.38 172 500
Metastasis 1. Progress right chest wall 110.09 88.96 174 580
Buffy Coat Baseline blood 117.94 88.56 173 -
Patient 3
Metastasis 1 Baseline left chest wall 156.9 97.73 184 81
Metastasis 2 1. Progress left chest wall 151.96 98.34 164 251
Buffy Coat Baseline blood 158.27 97.95 164 -
Patient 4
Tumor Baseline left kidney 109.85 88.33 172 371
Metastasis 1 1. Progress os ilium 117.01 90.06 176 342
Metastasis 2 2. Progress left chest wall 126.32 87.42 167 770
BuffyCoat Baseline blood 120.94 90.53 174 -
  Mean 124.53 90.29 171.23 486
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included 11 male and six female patients with a median 
age of 65 years (range: 46 to 82 years) at the date of initial 
diagnosis. Four patients had initial tumor stage T1, one 
patient T2, nine patients T3, and two patients T4 disease. 
Sixteen patients had already developed metastatic disease 
at diagnosis. Of the 17 recruited patients, four progressed 
under TKI treatment and were subjected to the molecular 
analyses (Table 1). Selection criteria for these four patients 
were the disease progression and the availability of high 
quality DNA from progressive metastases. Six primary 
tumor and three normal adjacent tissue specimens from 
each patient were taken upon resection and immediately 
frozen in liquid nitrogen. Biopsies were taken during 
tumor progression. The histology of all tissue samples 
were confirmed by a board-certified pathologist. Unstained 
and unembedded samples with a median tumor cell 
fraction of 70% (range: 40–90%) were subjected to DNA 
isolation, followed by WES.
Isolation, quantification, and quality control of 
genomic DNA 
Fresh frozen surgical tumor tissue and biopsy 
samples (10–30 mg) were mechanically disrupted and 
homogenized using the TissueRuptor (Qiagen, Hilden, 
Germany). Genomic DNA was extracted using the 
QIAamp DNA Mini Kit (Qiagen) according to the 
manufacturer’s protocol. As germline control, genomic 
DNA from matched blood cells was isolated using 
the QIAamp DNA Blood Mini Kit (Qiagen). DNA 
concentrations were determined using the Qubit (Thermo 
Fisher Scientific, Waltham, MA, USA), and DNA integrity 
was assessed using the TapeStation (Agilent Technologies, 
Santa Clara, CA, USA). 
Library construction and exome sequencing
Sequencing libraries were prepared from 200 ng 
genomic DNA. Prior to library preparation, all DNA 
samples were sheared to an average fragment length of 
150 bp using the Covaris S220 ultrasonicator. Exome-
enriched sequencing libraries were prepared using the 
Agilent SureSelectXT Human All Exon V5+UTR kit (low 
input protocol). Library sizes and qualities were evaluated 
before and after capture by Bioanalyzer 2100 analysis using 
the High Sensitivity DNA Kit (Agilent) and quantified 
using the Qubit dsDNA HS Assay kit (Thermo Fisher 
Scientific). All libraries were subjected to 100 bp paired-
end sequencing on the Illumina HiSeq 2000 v3 at the 
DKFZ Genomics and Proteomics Core Facility. Selected 
variants were further validated by bidirectional Sanger 
sequencing on an ABI 3130 Genetic Analyzer (Thermo 
Fisher Scientific, Waltham, USA) using the BigDye 
Terminator v1.1 Cycle Sequencing Kit (Thermo Fisher 
Scientific, Waltham, USA) as described previously [28]. 
NGS data analysis and variant calling
Sequence data analysis and mutation calling was 
performed using the One Touch Pipeline (OTP), a fully 
automated computational platform for sequence analysis. 
Briefly, raw FASTQ data files and metadata were loaded 
into OTP. After quality score estimation using FastQC, 
the files were aligned to the human genome (hg19) using 
BWA [29]. All aligned files were subsequently merged 
with Picard. Files belonging to one same sample were 
combined into one file, which was quality controlled using 
a variety of in-house tools and standard SAMtools [30]. 
PCR duplicates were removed, and only unique reads 
were used for variant calling and target coverage 
estimation. After processing of bam files, an in-house 
SNV calling pipeline, consisting of three different steps 
(calling, annotation, and filtering) was used based on each 
tumor-control comparison. For variant calling, samtools, 
mpileup, and bcftools were used. Called variants were 
annotated using the dbSNP and COSMIC databases and 
filtered for somatic variants in protein coding regions 
with a mutant allele frequency of > 2.5%. If a mutation 
was found in only one of the matched primary/metastatic 
samples from the same patient, unfiltered somatic and non 
synonymous exonic variants were called independent of 
their allele frequencies.
Data availability
FASTQ files are available at the European Genome-
Phenome Archive (https://ega-archive.org/) under the 
accession number EGAS00001001861.
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